Outlook Therapeutics, Inc. (OTLK)

NASDAQ: OTLK · IEX Real-Time Price · USD
7.67
+0.01 (0.13%)
At close: Jun 14, 2024, 4:00 PM
7.38
-0.29 (-3.78%)
After-hours: Jun 14, 2024, 7:45 PM EDT
0.13%
Market Cap 179.52M
Revenue (ttm) n/a
Net Income (ttm) -159.13M
Shares Out 23.41M
EPS (ttm) -11.41
PE Ratio n/a
Forward PE 2.85
Dividend n/a
Ex-Dividend Date n/a
Volume 111,556
Open 7.57
Previous Close 7.66
Day's Range 7.57 - 7.96
52-Week Range 4.00 - 37.00
Beta 0.65
Analysts Strong Buy
Price Target 46.43 (+505.35%)
Earnings Date Aug 12, 2024

About OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The compa... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 13, 2016
Employees 24
Stock Exchange NASDAQ
Ticker Symbol OTLK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for OTLK stock is "Strong Buy." The 12-month stock price forecast is $46.43, which is an increase of 505.35% from the latest price.

Price Target
$46.43
(505.35% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series

Live webcast on Thursday, June 13th at 4:00 PM ET FRENCHTOWN, NJ / ACCESSWIRE / June 12, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announc...

3 days ago - Accesswire

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizum...

4 days ago - GlobeNewsWire

Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Watch the "What This Means" video here Outlook CEO, Russ Trenary underscores that LYTENAVA™ (bevacizumab gamma) has become the first ophthalmic formulation of bevacizumab to receive European Commissio...

9 days ago - Accesswire

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

ISELIN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizuma...

18 days ago - GlobeNewsWire

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

ISELIN, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first authorized use of an ophthalm...

4 weeks ago - GlobeNewsWire

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

ISELIN, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first authorized use of an ophthalm...

4 weeks ago - GlobeNewsWire

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab...

5 weeks ago - GlobeNewsWire

Outlook Therapeutics® to Present at the Retina World Congress 2024

ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab...

6 weeks ago - GlobeNewsWire

Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizum...

6 weeks ago - GlobeNewsWire

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizum...

2 months ago - GlobeNewsWire

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

ISELIN, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizum...

3 months ago - GlobeNewsWire

Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizum...

3 months ago - GlobeNewsWire

Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

ISELIN, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formula...

3 months ago - GlobeNewsWire

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

ISELIN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first ophthalmic formulation of be...

4 months ago - GlobeNewsWire

Outlook Therapeutics® Doses First Subject in NORSE EIGHT

ISELIN, N.J., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizum...

4 months ago - GlobeNewsWire

Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010

ISELIN, N.J., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizum...

5 months ago - GlobeNewsWire

OTLK FINAL DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK

NEW YORK , Jan. 2, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December 29, 2022 ...

5 months ago - PRNewsWire

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , Jan. 2, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK) of a class action securities lawsuit. CLASS D...

5 months ago - PRNewsWire

OTLK DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action – OTLK

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December 29, 2022 and August 29...

5 months ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OTLK

NEW YORK , Dec. 28, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK) and certain o...

6 months ago - PRNewsWire

OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit

LOS ANGELES , Dec. 28, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit agai...

6 months ago - PRNewsWire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Outlook Therapeutics, Inc. (OTLK)

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investo...

6 months ago - Business Wire

OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $50,000 investing in Outlook securities between August 3, 2021 and August 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilso...

6 months ago - PRNewsWire

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outlook Therapeutics, Inc. ("...

6 months ago - Accesswire

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK

NEW YORK , Dec. 26, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December 29, 2022...

6 months ago - PRNewsWire